ACRO Biomedical Co., Ltd. (TPEX:6748)
Taiwan · Delayed Price · Currency is TWD 71.20
+0.40 (0.56%)
May 8, 2026, 1:53 PM CST
ACRO Biomedical Revenue
In the year 2025, ACRO Biomedical had annual revenue of 38.26M TWD, down -13.51%. ACRO Biomedical had revenue of 13.32M in the half year ending June 30, 2025, a decrease of -15.74%.
Revenue
38.26M
Revenue Growth
-13.51%
P/S Ratio
113.62
Revenue / Employee
n/a
Employees
34
Market Cap
4.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 38.26M | -5.98M | -13.51% |
| Dec 31, 2024 | 44.23M | -6.83M | -13.38% |
| Dec 31, 2023 | 51.06M | 23.43M | 84.79% |
| Dec 31, 2022 | 27.63M | 5.81M | 26.59% |
| Dec 31, 2021 | 21.83M | 3.80M | 21.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medigen Biotechnology | 1.58B |
| Sagittarius Life Science | 346.08M |
| BioGend Therapeutics | 229.81M |
| Pharmosa Biopharm | 67.27M |
| OBI Pharma | 58.58M |
| UnicoCell Biomed | 30.10M |
| Formosa Pharmaceuticals | 9.50M |
| Energenesis Biomedical CO.,LTD. | 7.67M |